Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 602

1.

Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.

Morag-Sela T, Cohn I, Kowalski TJ, Jarecki-Black J, Clyde-Watson Z.

Nat Biotechnol. 2004 Dec;22(12):1591-2. No abstract available.

PMID:
15583670
2.

Drug marketing exclusivity under United States and European Union law.

Junod V.

Food Drug Law J. 2004;59(4):479-518. No abstract available.

PMID:
15875347
3.

Balancing innovation, access, and profits--market exclusivity for biologics.

Engelberg AB, Kesselheim AS, Avorn J.

N Engl J Med. 2009 Nov 12;361(20):1917-9. doi: 10.1056/NEJMp0908496. Epub 2009 Oct 14. No abstract available. Erratum in: N Engl J Med. 2010 Dec 9;363(24):2374. N Engl J Med. 2010 Feb 18;362(7):664.

4.

The World Health Organization's prequalification program and its potential effect on data exclusivity laws.

Childs DW.

Food Drug Law J. 2005;60(1):79-97. No abstract available.

PMID:
15940855
5.

Branded drug reformulation: the next brand vs. generic antitrust battleground.

Amoresano GV.

Food Drug Law J. 2007;62(1):249-56. No abstract available.

PMID:
17444032
6.

Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.

Buckely M.

Seton Hall Law Rev. 2011;41(2):625-69. No abstract available.

PMID:
21739760
7.

Intellectual property. Balancing innovation and access: patent challenges tip the scales.

Higgins MJ, Graham SJ.

Science. 2009 Oct 16;326(5951):370-1. doi: 10.1126/science.1176116. No abstract available.

PMID:
19833944
8.

FDA's role in making exclusivity determinations.

Dickinson EH.

Food Drug Law J. 1999;54(2):195-203. No abstract available.

PMID:
11758573
9.

Indian biogenerics industry emerges.

Jayaraman KS.

Nat Biotechnol. 2003 Oct;21(10):1115-6. No abstract available.

PMID:
14520378
10.

EU to review rare disease drugs market exclusivity.

Sheridan C.

Nat Biotechnol. 2004 Sep;22(9):1061. No abstract available.

PMID:
15340455
11.

Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress.

Wolff ME.

J Pharm Sci. 2011 Aug;100(8):3044-54. doi: 10.1002/jps.22564. Epub 2011 Apr 6.

PMID:
21472728
12.

Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective.

Viana JM.

Conn J Int Law. 2002 Spring;17(2):311-8. No abstract available.

PMID:
12688298
13.

Policy making on data exclusivity in the European Union: from industrial interests to legal realities.

Adamini S, Maarse H, Versluis E, Light DW.

J Health Polit Policy Law. 2009 Dec;34(6):979-1010. doi: 10.1215/03616878-2009-033.

PMID:
20018988
15.

US courts narrow patent exemptions.

Fox JL.

Nat Biotechnol. 2003 Aug;21(8):834. No abstract available.

PMID:
12894182
16.

Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.

Gorlin DI.

Food Drug Law J. 2008;63(4):823-64. No abstract available.

PMID:
19601385
17.

GATT implementation and generic drug approval.

Safir PO, Lassman SM.

Food Drug Law J. 1996;51(2):295-302. No abstract available.

PMID:
11820203
18.

Intellectual property. Challenges to India's pharmaceutical patent laws.

Sampat BN, Shadlen KC, Amin TM.

Science. 2012 Jul 27;337(6093):414-5. doi: 10.1126/science.1224892. Epub 2012 Jul 5. No abstract available.

PMID:
22767892
19.

Patent watch.

Harrison C.

Nat Rev Drug Discov. 2008 Nov;7(11):882-3. doi: 10.1038/nrd2751. No abstract available.

PMID:
18974746
20.

US policy may encourage counterfeit drugs.

Bouchie A.

Nat Biotechnol. 2003 Feb;21(2):121. No abstract available.

PMID:
12560826

Supplemental Content

Support Center